Want to see FR:ALVAL full AI Analyst Report?
Top Page
Valbiotis SA
(ALVAL)
Select Model
Select Model
Rating:43Neutral
Price Target:
€0.61
▼(-25.19% Downside)
Action:Reiterated
Date:10/15/26
The score is held down primarily by weak financial performance (persistent losses and sustained cash burn) and bearish technicals (price below key moving averages with negative MACD and oversold-like momentum). Valuation provides limited support because the negative P/E is not meaningful and there is no dividend yield data.
Positive Factors
Nutrition-health product focus
Valbiotis operates in the nutrition-health intersection, targeting prevention and support for cardiometabolic conditions. Its focus on plant-based or bioactive formulations and clinical evaluation provides a defined platform for developing products that may address expanding health and prevention needs.
Negative Factors
Persistent unprofitability
The scale of the 2025 net loss relative to revenue shows that Valbiotis remains far from operating profitability. Continued losses can consume capital, constrain investment choices, and make the business dependent on future commercial progress or additional financing to sustain development.
Read all positive and negative factors
Positive Factors
Negative Factors
Nutrition-health product focus
Valbiotis operates in the nutrition-health intersection, targeting prevention and support for cardiometabolic conditions. Its focus on plant-based or bioactive formulations and clinical evaluation provides a defined platform for developing products that may address expanding health and prevention needs.
Read all positive factors
Valbiotis SA (ALVAL) vs. iShares MSCI France ETF (EWQ)
Market Cap
€22.31M
Dividend YieldN/A
Average Volume (3M)134.86K
Price to Earnings (P/E)―
Beta (1Y)-0.15
Revenue Growth183.47%
EPS Growth57.15%
CountryFR
Employees50
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding35,538,235
10 Day Avg. Volume88,191
30 Day Avg. Volume134,864
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)€2.40M
Valbiotis SA Business Overview & Revenue Model
Company Description
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular disea...
How the Company Makes Money
Valbiotis makes money primarily by commercializing its nutrition-health products and/or the underlying ingredients/formulations it develops, generating revenue from product sales (direct-to-consumer and/or through distribution channels such as pha...
Valbiotis SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 905.00K | 175.00K | 4.73M | 785.00K | 298.00K |
| Gross Profit | -1.17M | -2.44M | 2.69M | 767.00K | 282.00K |
| EBITDA | -9.32M | -9.17M | -6.41M | -11.13M | -9.14M |
| Net Income | -9.42M | -10.03M | -7.37M | -12.31M | -8.68M |
Balance Sheet | |||||
| Total Assets | 14.39M | 19.61M | 33.31M | 27.17M | 28.48M |
| Cash, Cash Equivalents and Short-Term Investments | 8.68M | 11.58M | 25.02M | 20.83M | 21.82M |
| Total Debt | 5.09M | 5.72M | 6.88M | 7.18M | 7.59M |
| Total Liabilities | 7.43M | 9.24M | 13.71M | 13.86M | 14.25M |
| Stockholders Equity | 6.96M | 10.37M | 19.60M | 13.31M | 14.23M |
Cash Flow | |||||
| Free Cash Flow | -8.19M | -11.80M | -8.30M | -9.48M | -7.58M |
| Operating Cash Flow | -8.04M | -11.54M | -8.06M | -9.19M | -7.16M |
| Investing Cash Flow | -77.00K | -61.00K | -250.00K | -197.00K | -7.00K |
| Financing Cash Flow | 5.21M | -1.84M | 12.49M | 8.40M | 14.40M |
Valbiotis SA Technical Analysis
Neutral
0.81
Price Trends
0.69
Negative
0.75
Negative
0.87
Negative
Market Momentum
-0.02
Negative
51.91
Neutral
82.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVAL, the sentiment is Neutral. The current price of 0.81 is above the 20-day moving average (MA) of 0.58, above the 50-day MA of 0.69, and below the 200-day MA of 0.87, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 51.91 is Neutral, neither overbought nor oversold. The STOCH value of 82.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALVAL.
Valbiotis SA Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | €4.04M | 6.98 | ― | ― | -40.95% | -39.70% | |
50 Neutral | €760.35M | -6.00 | -1625.48% | ― | -99.64% | 68.67% | |
46 Neutral | €8.87M | -0.43 | 33.88% | ― | ― | ― | |
44 Neutral | €541.90M | -5.32 | 279.22% | ― | 27.70% | -162.89% | |
44 Neutral | €46.73M | -4.49 | -32.62% | ― | 3.22% | 24.05% | |
43 Neutral | €22.31M | -2.13 | -87.66% | ― | 183.47% | 57.15% |
* Consumer Defensive Sector Average
FR:ALVAL
Valbiotis SA
0.63
>-0.01
-0.95%
FR:GNFT
Genfit
10.86
7.31
205.92%
FR:IVA
Inventiva
3.18
-0.34
-9.66%
FR:POXEL
Poxel SA
0.17
-0.17
-50.30%
FR:ALGAE
Fermentalg SA
0.39
-0.09
-19.59%
FR:ALPAT
Plant Advanced Technologies SA
3.56
-4.94
-58.12%
Valbiotis SA Corporate Events
Valbiotis Adds Amazon France as New Digital Channel for Cardiometabolic Health Products
Oct 26, 2026
Valbiotis is expanding its distribution strategy by launching all its ValbiotisPRO and ValbiotisPLUS natural cardiometabolic health ranges on Amazon France, complementing its existing pharmacy and direct online sales channels. By entering France&#...
Valbiotis Wins Double “Best Pharma Product 2027” Award in Cardiometabolic Health
Oct 19, 2026
Valbiotis has received a double “Best Pharma Product 2027” award for its Valbiotis PRO® Cholesterol and Valbiotis PRO® Metabolic Health solutions, following tests conducted by independent consumers in real-life conditions. Th...
Valbiotis updates share capital and voting rights, reinforces ownership disclosure rules
Oct 12, 2026
Valbiotis SA has reported its monthly share capital and voting rights status as of 30 September 2026, with 35,538,234 shares outstanding and 36,201,630 exercisable voting rights on Euronext Growth Paris. The disclosure reinforces transparency for ...
Valbiotis Study Clears Path for Launch of Liver Health Product
Sep 22, 2026
Valbiotis reported positive results from its randomized, placebo-controlled Cardio-Liver study in 71 overweight or obese volunteers with hepatic steatosis, showing Steadrive reduces liver fat and improves several metabolic parameters. These findin...
Valbiotis updates share capital and voting rights, reinforces governance transparency
Sep 7, 2026
Valbiotis SA has published its monthly regulatory update on the composition of its share capital and voting rights as of August 31, 2026, in line with Article 223-16 of the AMF’s General Regulation. The company reports 35,538,234 shares outs...
Valbiotis Reports July 2026 Share Capital and Voting Rights
Aug 17, 2026
Valbiotis SA has reported its monthly share capital and voting rights position as of July 31, 2026, in line with French market regulation. The company’s share capital stands at 35,538,234 shares, corresponding to 36,250,779 theoretical votin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.